Understanding how Scap protein affects the production of harmful lipoproteins
Targeting Scap to Lower ApoB-Containing Lipoproteins (ApoBCL) Production
This study is looking at how a protein called Scap helps control the production of certain fats in the body that can lead to heart disease, especially in people who are taking medications like statins or PCSK9 inhibitors, and the researchers hope to find a way to block Scap to help lower these harmful fats in the blood and improve heart health.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project ID | NIH-11004398 on NIH RePORTER |
What this research studies
This research investigates the role of the Scap protein in controlling the production of ApoB-Containing Lipoproteins (ApoBCLs), which are linked to coronary heart disease, especially in patients who have undergone treatment with statins or PCSK9 inhibitors. The study aims to uncover the molecular mechanisms by which Scap interacts with other proteins to regulate lipid synthesis. By developing a compound that can inhibit Scap, the researchers hope to provide new insights into reducing the levels of these harmful lipoproteins in the bloodstream. This could lead to innovative therapeutic strategies for patients at risk of heart disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with elevated levels of triglyceride-rich ApoBCLs, particularly those who have not achieved desired outcomes with current lipid-lowering therapies.
Not a fit: Patients who do not have elevated ApoBCL levels or those who are not at risk for coronary heart disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly lower the risk of coronary heart disease by reducing harmful lipoprotein levels in patients.
How similar studies have performed: Other research has shown promising results in targeting similar pathways for reducing lipoprotein levels, indicating that this approach has potential for success.
Where this research is happening
Dallas, United States
- Ut Southwestern Medical Center — Dallas, United States (Active)
Researchers
- Principal investigator: Radhakrishnan, Arun — Ut Southwestern Medical Center
- Study coordinator: Radhakrishnan, Arun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.